![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
The effects of the prostaglandin E1 analogue misoprostol on base-line and stimulated (gastrin, histamine, and the muscarinic Ml agonist McN-A-343) acid secretion, base-line and gastrin-stimulated histamine release, and base-line and McN-A-343-stimulated gastrin release in the totally isolated, vascularly perfused rat stomach were studied. At a concentration of 1 nM, misoprostol significantly (p < 0.01) inhibited base-line acid secretion from 13.7 ± 2.7 to 4.8 ± 0.7 μmol/60 min, histamine-stimulated acid secretion from 99.9 ± 15.1 to 21.8 ± 8.2 μmol/60 min, maximal gastrin-stimulated secretion from 92.5 1± 11.4 to 3.1 ± 0.6 μmol/60 min, and maximal McN-A-343-stimulated secretion from 60.0 ± 8.9 to 6.8 ± 2.6 μmol/60 min (mean ± SEM). Likewise, misoprostol significantly inhibited base-line vascular histamine release (p < 0.05) from 10.1 ± 2.3 to 3.7 ± 0.7 nmol/60 min and gastrin-stimulated release (p < 0.01) from 54.7 ± 7.9 to 20.2 ± 4.1 nmol/60 min (mean ± SEM). The gastrin release was not affected by misoprostol. We conclude that misoprostol inhibits acid secretion both by a direct effect on the parietal cell and by inhibiting endogenous histamine release.